FDA
-
-
-
-
-
-
-
Unicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA)
-
-
-
-
-
-
-
Unicycive Therapeutics (UNCY) PT Lowered to $15 at Benchmark
-
-
-
-
-
-
-
Important Notice to Long-Term Shareholders of Corcept Therapeutics, Inc. (NASDAQ: CORT); Kyndryl Holdings (NYSE: KD); Molina Healthcare, Inc. (NYSE: MOH); and Unicycive Therapeutics, Inc. (NASDAQ: UN
-
-
-
-
-
-
-
Unicycive resubmits drug application for kidney disease treatment
-
-
-
-
-
-
-
Unicycive Therapeutics (UNCY) PT Lowered to $63 at Lucid Capital Markets
-
-
-
-
-
-
-
Unicycive expects to resubmit drug application by year-end after FDA meeting
-
-
-
-
-
-
-
Unicycive Therapeutics (UNCY) PT Raised to $21 at Benchmark to Reflect Reverse Split
-
328,517 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

